Original Publication Date: 1 March, 2017
Publication / Source: Melanoma Management
Authors: Hugo Arasanz, Alejandra Lacalle, Maria José Lecumberri et al
Immunotherapy has radically transformed the management of metastatic malignant melanoma. Ipilimumab, a CTLA-4-targeted monoclonal antibody, was the first immunotherapeutic drug to reach a survival benefit compared with traditional chemotherapy. PD-1 targeted therapies, pembrolizumab and nivolumab, have demonstrated, in recent clinical trials, to be even more effective and safer.